Hand-foot syndrome and survival in patients with advanced non-small-cell lung cancer receiving anlotinib: a subgroup analysis of data from the ALTER 0303 study

被引：0
|
作者：
Xueli Nan
Chao Xie
Qingqing Zhu
Jianjun Zhang
Shuai Fu
Xiao Han
Qiujing Zhang
Baohui Han
Jie Liu
机构：
[1] Shandong First Medical University and Shandong Academy of Medical Sciences,Department of Oncology
[2] Wu Di People Hospital,Department of Oncology
[3] Shandong Cancer Hospital and Institute,School of Medicine and Life Sciences
[4] University of Ji’nan-Shandong Academy of Medical Sciences,Department of Pulmonary Medicine
[5] Shanghai Chest Hospital,undefined
来源：
International Journal of Clinical Oncology | 2020年 / 25卷
关键词：
Non-small-cell lung cancer; Anlotinib; Adverse event; Clinical marker;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1492 / 1498
页数：6
相关论文
共 50 条
  • [21] Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: subgroup analysis in the ALTER0303 trial (vol 9, pg 2621, 2020)
    Cheng, Ying
    CANCER MEDICINE, 2021, 10 (07): : 2523 - 2525
  • [22] Quality of Life in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Palliative Chemotherapy
    Daroszewski, Cyryl
    Stasiewicz, Malgorzata
    Jazwinska-Tarnawska, Ewa
    Rachwalik, Anna
    Mura, Ewa
    Luboch-Kowal, Joanna
    Drys, Andrzej
    Bogucki, Zdzislaw A.
    Brzecka, Anna
    ADVANCES IN PULMONARY MEDICINE: RESEARCH AND INNOVATIONS, 2019, 1160 : 11 - 18
  • [23] Overall survival benefit in advanced non-small-cell lung cancer
    Owen, Olwen Glynn
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2008, 69 (07) : 379 - 379
  • [24] Atezolizumab in Japanese Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis of the Phase 3 OAK Study
    Hida, Toyoaki
    Kaji, Reiko
    Satouchi, Miyako
    Ikeda, Norihiko
    Horiike, Atsushi
    Nokihara, Hiroshi
    Seto, Takashi
    Kawakami, Tomohisa
    Nakagawa, Shintaro
    Kubo, Toshio
    CLINICAL LUNG CANCER, 2018, 19 (04) : E405 - E415
  • [25] EFFICACY AND SAFETY OF ANLOTINIB COMBINED WITH ICOTINIB IN THE TREATMENT OF ADVANCED NON-SMALL-CELL LUNG CANCER
    Chen, Hualin
    Luo, Yiping
    Lin, Muwen
    Peng, Xiaoxia
    Liu, Meilian
    Huang, Zhong
    Wang, Yongcun
    Li, Shujun
    Yang, Donghong
    Yang, Zhixiong
    ACTA MEDICA MEDITERRANEA, 2022, 38 (03): : 2035 - 2040
  • [26] SURVIVAL ANALYSIS OF UNTREATED PATIENTS WITH NON-SMALL-CELL LUNG-CANCER
    VRDOLJAK, E
    MISE, K
    SAPUNAR, D
    ROZGA, A
    MARUSIC, M
    CHEST, 1994, 106 (06) : 1797 - 1800
  • [27] IMPROVED SURVIVAL FOR PATIENTS WITH ADVANCED NON-SMALL-CELL CARCINOMA OF THE LUNG
    MILLER, TP
    ARIZONA MEDICINE, 1979, 36 (12) : 893 - &
  • [28] Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer
    Yoshimoto, Nobuyasu
    Yamashita, Toshinari
    Fujita, Takashi
    Hayashi, Hironori
    Tsunoda, Nobuyuki
    Kimura, Mariko
    Tsuzuki, Norimasa
    Yamashita, Hiroko
    Toyama, Tatsuya
    Kondo, Naoto
    Iwata, Hiroji
    BREAST CANCER, 2010, 17 (04) : 298 - 302
  • [29] Does consolidation chemotherapy improves survival for locally advanced non-small-cell lung cancer patients receiving concurrent chemoradiotherapy?
    Komurcuoglu, Berna
    Vatansever, Yelda
    Korkmaz, Esra
    Evkan, Aysen
    Yalniz, Enver
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [30] Association Between Obesity and Poor Prognosis in Patients Receiving Anlotinib for Advanced Non-Small Cell Lung Cancer
    Xiong, Anning
    Nie, Wei
    Cheng, Lei
    Zhong, Hua
    Chu, Tianqing
    Zhong, Runbo
    Lu, Jun
    Wang, Shuyuan
    Xu, Jianlin
    Shen, Yinchen
    Pan, Feng
    Han, Baohui
    Zhang, Xueyan
    FRONTIERS IN PHARMACOLOGY, 2022, 13
12345